Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Congress Backs Alternatives to Opioids (ALTO) in the ED Program

By Ryan McBride | on March 17, 2020 | 0 Comment
ACEP4U
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

In December 2019, Congress authorized funding for the Alternatives to Opioids (ALTO) in the Emergency Department program—the final step in the legislative process needed to set the ALTO grant program in motion and another significant victory for ACEP’s federal advocacy efforts.

You Might Also Like
  • U.S. Congress Passes Comprehensive Opioid Package
  • ACEP Continues Multi-Front Efforts in Opioid Battle
  • Recent ACEP Advocacy in Texas, Congress, and Beyond
Explore This Issue
ACEP Now: Vol 39 – No 03 – March 2020

Background

The ALTO program was originally developed by ACEP President-Elect Mark Rosenberg, DO, MBA, FACEP, and Alexis LaPietra, DO, FACEP, and their team at St. Joseph’s University Medical Center in New Jersey in 2016. Intended to address issues of variation and overprescribing of opioids, ALTO is an evidence-based, multidisciplinary acute pain management program that helps treat painful conditions for patients in the emergency department without using opioids and also helps other patients who may have an opioid use disorder (OUD). In just one year after implementing the program, opioid prescriptions in the St. Joseph’s emergency department fell by 46 percent, and after two years, opioid prescriptions were down by 82 percent.

ACEP’s federal advocacy efforts to help expand the reach of the ALTO program began in 2017, and the path from introduction to authorization and appropriations was extraordinarily rapid by legislative standards. ACEP’s Washington, D.C., staff worked with Rep. Bill Pascrell (D-NJ) and Rep. David McKinley (R-WV), as well as Sen. Cory Booker (D-NJ), Sen. Shelley Moore Capito (R-WV), Sen. Michael Bennet (D-CO), and Sen. Cory Gardner (R-CO) to develop legislation that would establish a federal grant program to provide $10 million per year to help other emergency departments implement their own ALTO protocols.

On March 7, 2018, the Alternatives to Opioids in the Emergency Department Act was introduced in both the House and Senate (HR 5197/S 2516)—fortunately timed, as all of Congress’ attention was squarely focused on the nation’s opioid epidemic. ACEP received an invitation to testify about the ALTO program’s success before a House Committee on Energy & Commerce hearing on March 22, 2018, and Dr. Rosenberg testified on ACEP’s behalf. ACEP members advocated for ALTO during the annual Leadership & Advocacy Conference, and the bill was included among a number of other opioid-related bills that were marked up in the Energy & Commerce Health Subcommittee in April and the full committee in May. ALTO received a voice (unanimous) vote on the House floor in June, and it was then merged into the SUPPORT for Patients and Communities Act (HR 6), which was ultimately signed into law on Oct. 24, 2018. The ACEP-developed ALTO legislation went from introduction to enactment in a mere eight months.

Pages: 1 2 3 | Single Page

Topics: AdvocacyAlternatives to Opioids (ALTO)Opioid Crisis

Related

  • Pros and Cons: A Mandated Four-Year Residency

    June 11, 2025 - 1 Comment
  • ACEP 2025 Leadership & Advocacy Conference—Showing Up on Behalf of EM!

    June 5, 2025 - 0 Comment
  • June 2025 News from the College

    June 5, 2025 - 0 Comment

Current Issue

ACEP Now May 03

Download PDF

Read More

No Responses to “Congress Backs Alternatives to Opioids (ALTO) in the ED Program”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603